KRAS and colorectal carcinoma: Our study provides compelling evidence that KRAS G12A mutation is an independent and clinically useful adverse prognostic factor, identifying a distinct high-risk subset of resected stage II–III CRC patients characterized by early recurrence and inferior survival.